A Phase I Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Latest Information Update: 22 Jan 2024
At a glance
- Drugs Tabelecleucel (Primary) ; Cyclophosphamide
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 12 Dec 2023 Results assessing long-term follow-up after treatment with allogenic off the shelf CAR T Cell Therapy for the treatment of B cell malignancies ,presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 15 Aug 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2026.
- 15 Aug 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2026.